Results 181 to 190 of about 77,108 (288)

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

New England Journal of Medicine, 2015
M. Postow, J. Chesney, A. Pavlick, C. Robert, K. Grossmann, D. McDermott, G. Linette, N. Meyer, J. Giguere, S. Agarwala, M. Shaheen, M. Ernstoff, D. Minor, A. Salama, Matthew H. Taylor, P. Ott, L. Rollin, C. Horak, P. Gagnier, J. Wolchok, F. Hodi   +20 more
semanticscholar   +1 more source

Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population. [PDF]

Cancer Immunol Immunother
Weber M, Freiherr von Hammerstein-Equord A, Weinreich M, Andreas S, Rittmeyer A.   +4 more
europepmc   +1 more source

Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele

Cancer, Volume 132, Issue 3, 1 February 2026.
ABSTRACT Background While immune checkpoint inhibitors (ICIs) have shown significant efficacy, a common side effect is cutaneous immune‐related adverse events (irAEs). This study focuses on exploring the association between specific human leukocyte antigen (HLA) alleles and the development of cutaneous irAEs in melanoma patients undergoing ICI ...
Mckenzie DiLeo, Samantha Oglesby, Cheuk Hong Leung, Kristen E. Pauken, Sahira Farooq, Lauren E. Haydu, Shelby L. Kubicki, Rebeca Martinez, Macartney Welborn, Sana Zahiruddin, Jun Zou, Kai Cao, Anisha B. Patel   +12 more
wiley   +1 more source

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. [PDF]

J Immunother Cancer
O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH.   +22 more
europepmc   +1 more source

A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background We present the case of 72–year‐old male with metastatic de‐differentiated chondrosarcoma (“DDCS”). DDCS is a rare soft tissue cancer that carries a dismal prognosis in the metastatic stage, and is resistant to both traditional chemotherapy and radiotherapy. There is a distinct lack of proven systemic therapies. Case This case report
Matthew Youssef, Peter Grimison
wiley   +1 more source

Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management. [PDF]

Cureus
SirDeshpande P, Hegde SBS, Akhtar H.
europepmc   +1 more source

Primary Mediastinal Malignant Melanoma Presenting With Pleural Effusion: A Case Report

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Primary mediastinal malignant melanoma (PMMM) presenting with pleural effusion as the initial manifestation is exceedingly rare, presenting significant diagnostic and therapeutic challenges. This article reports a case of PMMM that initially manifested as pleural effusion and includes a review of the relevant literature.
Minlian Nong, Weifeng Wei, Naijian Li, Yunxiang Zeng, Jinlin Wang   +4 more
wiley   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis. [PDF]

Front Public Health
Wu Q, Qin Y, Li Q.
europepmc   +1 more source

Large Language Models for Clinical Trial Protocol Assessments

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 393-402, February 2026.
The purpose was to evaluate the utility of large language models (LLMs) for reviewing the statistical analysis plan (SAP) and pharmacokinetics–pharmacodynamics (PK–PD) components of clinical trial protocols. Clinical trial protocols and SAPs were obtained from clinicaltrials.gov for a testbed of 15 small‐molecule drugs, biologics, and global antibiotic
Euibeom Shin, Amruta Gajanan Bhat, Murali Ramanathan   +2 more
wiley   +1 more source

Severe bilateral chorioretinopathy associated with ipilimumab in a patient with metastatic melanoma. [PDF]

GMS Ophthalmol Cases
Asensio-Sánchez VM.
europepmc   +1 more source